AIM News and Press, AIM ImmunoTech Inc. From 05/18/22

OCALA, Fla., May 18, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral d...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips DecisionPoint Systems (NYSEMKT: DPSI ) stock is leading our top gainers. Target (NYSE: TGT ) stock is at the top of our losers list. Earnings reports are behind much of this morning’s stock movement....

- First quarter marked by peer-reviewed journal and abstract publications showcasing statistically significant efficacy data of Ampligen in late-stage pancreatic cancer; results also showcased continued positive data in ovarian and triple-negative breast cancer clinical studies as well as...

OCALA, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral d...

The shares of AIM ImmunoTech (NYSE:AIM) are rising the pre-market Thursday after the immuno-pharma company disclosed a summary of clinical data to back the synergistic effect of its cancer candidate Ampligen with checkpoint blockade therapies. A dsRNA drug, known as rintatolimod, Ampligen, is...

Capstone Green Energy (CGRN) +23% lands a service contract with one of the largest North American energy infrastructure companies. Mullen Automotive (MULN) +20% on conducting solid-state battery cell testing with BIC. AIM ImmunoTech (AIM) +13% provides summary of Ampligen ...

Ampligen has demonstrated in pre-clinical and now human clinical studies a potential to enhance efficacy of PD-1 and/or PD-L1 checkpoint inhibitors Ampligen’s anti-tumor potential is demonstrated with checkpoint blockade therapies in human clinical studies for the treatme...

Gainers: Lixte Biotechnology Holdings (LIXT) +205%. PolarityTE (PTE) +96%. Biodesix (BDSX) +29%. MiNK Therapeutics (INKT) +27%. Enservco (ENSV) +25%. Actinium Pharmaceuticals (ATNM) +21%. Compass Therapeutics (CMPX) +21%. Sunshine Biopharma (SBFM) +22%. Singularity Future Technology (SGLY) +2...

- Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with advanced pancreatic cancer - Company engages world-renowned CRO, Amarex Clinical Research LLC to conduct upcoming Phase 2 study ...

What to Know About Trading Penny Stocks on April 11th With another week of trading penny stocks getting off to an interesting start, there is a lot for investors to know. Considering that there is still an extremely high amount of volatility in the stock market, investors need to be on ...